Search research articles
Contact Us
Filters
Showing results (1-10 of 29) with videos related to
Page
of 3
Sort By:
The British Journal of Dermatology
|
October 8, 2020
Complete skin clearance and beyond
M Schmitt-Egenolf
The British Journal of Dermatology
|
February 15, 2018
What can we learn from 'dropouts' in clinical trials?
M Schmitt-Egenolf
The British Journal of Dermatology
|
September 17, 2016
Physical activity and lifestyle improvement in the management of psoriasis
M Schmitt-Egenolf
The British Journal of Dermatology
|
December 1, 2015
Evaluating equality in psoriasis healthcare: a cohort study of the impact of age on prescription of biologics
K Geale, M Henriksson, M Schmitt-Egenolf
The British Journal of Dermatology
|
June 24, 2017
Sustained Psoriasis Area and Severity Index, Dermatology Life Quality Index and EuroQol-5D response of biological treatment in psoriasis: 10 years of real-world data in the Swedish National Psoriasis Register
F Hjalte, K S Carlsson, M Schmitt-Egenolf
The British Journal of Dermatology
|
April 1, 2021
Prevalence and incidence of palmoplantar pustulosis in Sweden: a population-based register study
S Löfvendahl, J M Norlin, M Schmitt-Egenolf
Journal of the European Academy of Dermatology and Venereology : JEADV
|
June 10, 2014
Decision for biological treatment in real life is more strongly associated with the Psoriasis Area and Severity Index (PASI) than with the Dermatology Life Quality Index (DLQI)
D Hägg, A Sundström, M Eriksson, et al.
The British Journal of Dermatology
|
July 21, 2019
Complete skin clearance and Psoriasis Area and Severity Index response rates in clinical practice: predictors, health-related quality of life improvements and implications for treatment goals
J M Norlin, K Nilsson, U Persson, et al.
The Journal of Dermatological Treatment
|
January 31, 2017
Real-world outcomes in 2646 psoriasis patients: one in five has PASI ≥10 and/or DLQI ≥10 under ongoing systemic therapy
J M Norlin, P S Calara, U Persson, et al.
The British Journal of Dermatology
|
December 21, 2011
Analysis of three outcome measures in moderate to severe psoriasis: a registry-based study of 2450 patients
J M Norlin, K Steen Carlsson, U Persson, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 29) with videos related to
Sort By:
Page
of 3
The British Journal of Dermatology
|
October 8, 2020
Complete skin clearance and beyond
M Schmitt-Egenolf
The British Journal of Dermatology
|
February 15, 2018
What can we learn from 'dropouts' in clinical trials?
M Schmitt-Egenolf
The British Journal of Dermatology
|
September 17, 2016
Physical activity and lifestyle improvement in the management of psoriasis
M Schmitt-Egenolf
The British Journal of Dermatology
|
December 1, 2015
Evaluating equality in psoriasis healthcare: a cohort study of the impact of age on prescription of biologics
K Geale, M Henriksson, M Schmitt-Egenolf
The British Journal of Dermatology
|
June 24, 2017
Sustained Psoriasis Area and Severity Index, Dermatology Life Quality Index and EuroQol-5D response of biological treatment in psoriasis: 10 years of real-world data in the Swedish National Psoriasis Register
F Hjalte, K S Carlsson, M Schmitt-Egenolf
The British Journal of Dermatology
|
April 1, 2021
Prevalence and incidence of palmoplantar pustulosis in Sweden: a population-based register study
S Löfvendahl, J M Norlin, M Schmitt-Egenolf
Journal of the European Academy of Dermatology and Venereology : JEADV
|
June 10, 2014
Decision for biological treatment in real life is more strongly associated with the Psoriasis Area and Severity Index (PASI) than with the Dermatology Life Quality Index (DLQI)
D Hägg, A Sundström, M Eriksson, et al.
The British Journal of Dermatology
|
July 21, 2019
Complete skin clearance and Psoriasis Area and Severity Index response rates in clinical practice: predictors, health-related quality of life improvements and implications for treatment goals
J M Norlin, K Nilsson, U Persson, et al.
The Journal of Dermatological Treatment
|
January 31, 2017
Real-world outcomes in 2646 psoriasis patients: one in five has PASI ≥10 and/or DLQI ≥10 under ongoing systemic therapy
J M Norlin, P S Calara, U Persson, et al.
The British Journal of Dermatology
|
December 21, 2011
Analysis of three outcome measures in moderate to severe psoriasis: a registry-based study of 2450 patients
J M Norlin, K Steen Carlsson, U Persson, et al.
Page
of 3